Client Success Stories

From Animal Models to Clinical Trials: Accelerating IND Strategy for a Solo-Founder Pharma Company
A solo-founder U.S. pharma company had decades of research and animal model data but needed a clear path to clinical development. Facet provided strategic IND guidance to help translate promising preclinical results into investigator-initiated trials across multiple disease states.

Streamlining PET Radiopharmaceutical Development for a European Diagnostics Company
A European medical imaging company developing a novel PET radiopharmaceutical had accumulated ex-US data from over 800 patients but lacked a clear U.S. regulatory strategy. Facet stepped in to streamline development planning and reduce time and cost to approval.

The Journey from Phase 3 to 505(b)(2) Submission: Closing Biometrics Gaps for a Small Pharma Team
A small U.S. pharma team was 12 months from a 505(b)(2) submission with critical biometrics gaps and no internal resources to fill them. Facet embedded expert support to close those gaps and keep the program on track.
Awards & Recognition







gET sOCIAL